EA200900531A1 - Фармацевтические составы - Google Patents

Фармацевтические составы

Info

Publication number
EA200900531A1
EA200900531A1 EA200900531A EA200900531A EA200900531A1 EA 200900531 A1 EA200900531 A1 EA 200900531A1 EA 200900531 A EA200900531 A EA 200900531A EA 200900531 A EA200900531 A EA 200900531A EA 200900531 A1 EA200900531 A1 EA 200900531A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical compositions
active substance
composition
acid salt
polymer matrix
Prior art date
Application number
EA200900531A
Other languages
English (en)
Russian (ru)
Inventor
Йи Гао
Р. Йю Тцучи
Деннис Й. Ли
Николь Нгуен
Хауилианг Ву
Original Assignee
Эббот Лаборейторис
Форнэр Лаборейторис Айерлэнд Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эббот Лаборейторис, Форнэр Лаборейторис Айерлэнд Лтд. filed Critical Эббот Лаборейторис
Publication of EA200900531A1 publication Critical patent/EA200900531A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA200900531A 2006-10-12 2007-10-12 Фармацевтические составы EA200900531A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82925506P 2006-10-12 2006-10-12
PCT/US2007/081267 WO2008046052A1 (en) 2006-10-12 2007-10-12 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
EA200900531A1 true EA200900531A1 (ru) 2009-12-30

Family

ID=38961056

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900531A EA200900531A1 (ru) 2006-10-12 2007-10-12 Фармацевтические составы

Country Status (14)

Country Link
EP (1) EP2081563A1 (enExample)
JP (1) JP2010506855A (enExample)
KR (1) KR20090119959A (enExample)
CN (1) CN101677981A (enExample)
AU (1) AU2007307641A1 (enExample)
CA (1) CA2672686A1 (enExample)
CO (1) CO6160302A2 (enExample)
EA (1) EA200900531A1 (enExample)
EC (1) ECSP099251A (enExample)
IL (1) IL198160A0 (enExample)
MX (1) MX2009003815A (enExample)
SG (1) SG175570A1 (enExample)
WO (1) WO2008046052A1 (enExample)
ZA (1) ZA200902488B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2285357B8 (en) * 2008-05-30 2014-07-23 UCB Pharma, S.A. Pharmaceutical compositions comprising brivaracetam
CN102304103A (zh) * 2011-06-03 2012-01-04 郑州泰基鸿诺药物科技有限公司 一种非诺贝特酸盐、制备方法、药物组合物及应用
CN102659570B (zh) * 2012-05-17 2014-05-28 安润医药科技（苏州）有限公司 二氟非诺贝特酸及其在药学上可接受的盐，以及它们的制备方法和应用
FR3050112B1 (fr) * 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
CN107496397A (zh) * 2016-06-14 2017-12-22 重庆安格龙翔医药科技有限公司 一种二甲双胍与非诺贝酸的复合物及其制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
EP1832285A1 (en) * 2002-12-17 2007-09-12 Abbott GmbH & Co. KG Formulation comprising fenofibric acid or a physiologically acceptable salt thereof
EP1572190B1 (en) * 2002-12-17 2007-04-18 Abbott GmbH & Co. KG Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
MX2007012443A (es) * 2005-04-08 2007-12-13 Abbott Lab Formulaciones farmaceuticas orales que comprenden acido fenofibrico y/o sus sales.

Also Published As

Publication number Publication date
IL198160A0 (en) 2009-12-24
CO6160302A2 (es) 2010-05-20
CN101677981A (zh) 2010-03-24
JP2010506855A (ja) 2010-03-04
AU2007307641A1 (en) 2008-04-17
ECSP099251A (es) 2009-06-30
MX2009003815A (es) 2009-09-07
KR20090119959A (ko) 2009-11-23
WO2008046052A1 (en) 2008-04-17
SG175570A1 (en) 2011-11-28
CA2672686A1 (en) 2008-04-17
EP2081563A1 (en) 2009-07-29
ZA200902488B (en) 2010-10-27

Similar Documents

Publication Publication Date Title
Han et al. Advances in hemostatic hydrogels that can adhere to wet surfaces
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
BRPI0811948A2 (pt) Novo agente para a liberação de princípios ativos em curativos que contenham ao menos uma susbtância gordurosa
EA200802184A1 (ru) Фармацевтические композиции с ингибиторами dpp iv
WO2008137758A3 (en) Amino acid lipids and uses thereof
CA2784827C (en) Composition of dexibuprofen transdermal hydrogel
BRPI0820665A2 (pt) compostos de peptidil nitrilas, processos para fabricação dos mesmos, composição farmacêutica, combinação e uso de ditos compostos
EA200901365A1 (ru) Стабилизированная фармацевтическая композиция, содержащая прегабалин
CR9704A (es) Composicion farmaceutica de liberacion modificada, proceso de preparacion y metodo para emplear la misma.
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
WO2007085629A3 (en) Use of hyaluronic acid as a carrier molecule for?different classes of therapeutic active agents
WO2008149035A3 (fr) Nouveau principe actif dans la cicatrisation et son utilisation
WO2008124617A3 (en) Rapidly dissolving pharmaceutical compositions comprising pullulan
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
ATE543507T1 (de) Sdf-1 enthaltende zusammensetzung mit anhaltender freisetzung
ECSP099439A (es) Composición de liberación sostenida y métodos para producirla
RU2010153904A (ru) Ниацин-содержащие композиции с модифицированным высвобождением
TR201820076T4 (tr) İlaç kombinasyonlarının salımı.
MX2009003815A (es) Formulaciones farmaceuticas.
EA201100287A1 (ru) Композиция ропинирола
NO20082848L (no) Farmasoytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre
ITRM20050393A1 (it) Sistema di rilascio controllato di sostanze farmacologicamente attive, processo di preparazione e impieghi in campo medico.
UY30126A1 (es) Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones
EA201190050A1 (ru) Композиция кветиапина
ATE438385T1 (de) Pharmazeutische zusammensetzung